= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Ohlson

MSACL 2018 EU Abstract

Topic: Various Other

Podium Presentation in the Ether on Wednesday at 9:40 (Chair: Flaminia Fanelli)

Direct Analysis - No Sample Preparation - of Bioavailable Cortisol in Human Plasma by Weak Affinity Chromatography (WAC; Affinity LC/MS)

Sten Ohlson (Presenter)
Nanyang Technological University

Presenter Bio(s): Prof. Sten Ohlson is a biochemist graduated with a doctor degree from Lund University, Sweden in 1980. After academic studies, Sten Ohlson joined the biotechnology- and life science industry in Sweden (Gambro, Perstorp) and USA (HyClone Labs) where he spent thirteen years as manager and director of research. In 1993, he returned to Academia where he was a founding associate professor of the Biomedical Chemistry Centre of the University of Kalmar in Sweden. In 1999, Sten Ohlson was appointed a full professor in Applied Biochemistry and head of the biotechnology division at the University of Kalmar and later in 2010 he was a professor and head of the biotechnology group of Linnaeus University of Sweden. In 2013 he became a visiting professor followed by a full professorship in Applied Biochemistry at the School of Biological Sciences (SBS) at Nanyang Technological University (NTU), Singapore.

He is recognized for his pioneering contributions in cell culture engineering (whole-cell catalysts and novel cell culture growth media), in biosensor techniques for studies on transient biological interactions and most importantly the introduction of novel techniques in affinity chromatography ((High Performance Liquid Affinity Chromatography (HPLAC) and Weak Affinity Chromatography (WAC)). Of special importance has been the application of WAC for drug discovery and clinical diagnostics. Further, he has introduced the concepts of transient drugs and continuous biosensors based on dynamic biological interactions.

In 2017, he was the recipient of the ISMR Affinity Award for outstanding contributions to the field of affinity technology. Sten Ohlson is also a bioentrepreneur and he has founded four life-science companies in Sweden (Perstorp Biolytica, ProLiff, KalBiotech and Transientic Interactions).

Authors: Sten Ohlson
Nanyang Technological University, Singapore 637551

Abstract

Pre-analytical treatment of blood plasma is a time consuming and often rate limiting step in the workflow of LC/MS analysis. We present in this study a new approach for quantitative LC/MS based clinical analysis based on Weak Affinity Chromatography (WAC) making sample preparation obsolete.


Financial Disclosure

DescriptionY/NSource
GrantsyesPET
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no